piperidines and Child-Behavior-Disorders

The present study was designed as a 12-week, randomized, double-blind, placebo-controlled pilot study to evaluate the effectiveness and safety of donepezil in boys with fragile X syndrome. Twenty boys with fragile X syndrome were randomized to receive 12 weeks of treatment with either placebo or donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks). The outcome measures included change in intelligence quotient scores on Stanford-Binet Intelligence Scale (Hindi adaptation by Kulshrestha), change in behavioral scores by Conners 3 Parent Rating Scale (Short) and Childhood Autism Rating Scale, safety, and tolerability of donepezil. The study failed to show significant difference in intelligence quotient and behavioral scales with donepezil therapy over 12 weeks. However, donepezil appeared to be safe and well tolerated.

Topics: Adolescent; Child; Child Behavior Disorders; Child Development Disorders, Pervasive; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fragile X Syndrome; Humans; Indans; Intelligence; Male; Nootropic Agents; Personality Assessment; Pilot Projects; Piperidines; Stanford-Binet Test; Treatment Outcome

A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the primary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.

Topics: Adolescent; Adult; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Dioxoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eruptions; Female; Fragile X Syndrome; Humans; Long-Term Potentiation; Male; Neuronal Plasticity; Neuropsychological Tests; Personality Assessment; Piperidines; Receptors, AMPA; Synaptic Transmission; Treatment Outcome

Topics: Adolescent; Aggression; Child; Child Behavior Disorders; Chlorpromazine; Clinical Trials as Topic; Diazepam; Evaluation Studies as Topic; Female; Humans; Male; Mental Disorders; Motor Activity; Nitriles; Phenothiazines; Piperidines; Placebos; Tranquilizing Agents

Topics: Adolescent; Aggression; Antipsychotic Agents; Bipolar Disorder; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Isoxazoles; Lithium; Male; Piperidines; Risperidone

Topics: Benzhydryl Compounds; Child; Child Behavior Disorders; Histamine H1 Antagonists; Humans; Methylphenidate; Motor Activity; Piperidines

Topics: Adolescent; Aggression; Anxiety; Child; Child Behavior Disorders; Child, Preschool; Humans; Mental Disorders; Nitriles; Phenothiazines; Piperidines; Social Behavior Disorders; Tranquilizing Agents

Topics: Adolescent; Character; Child; Child Behavior Disorders; Child, Preschool; Female; Humans; Male; Nitriles; Personality Disorders; Phenothiazines; Piperidines; Tranquilizing Agents

Topics: Adolescent; Adult; Child; Child Behavior Disorders; Humans; Intellectual Disability; Nitriles; Phenothiazines; Piperidines; Tranquilizing Agents

Topics: Amphetamine; Anticonvulsants; Antidepressive Agents; Child; Child Behavior Disorders; Chlordiazepoxide; Diphenhydramine; Humans; Hypnotics and Sedatives; Meprobamate; Phytotherapy; Piperazines; Piperidines; Plants, Medicinal; Psychopharmacology; Psychotherapy; Rauwolfia; Time Factors

Topics: Adolescent; Antidepressive Agents; Aspartate Aminotransferases; Attention; Brain Damage, Chronic; Butyrophenones; Child; Child Behavior Disorders; Child, Preschool; Fluorine; Humans; Piperidines; Psychotic Disorders; Schizophrenia, Childhood; Trifluperidol

Topics: Adolescent; Adult; Child; Child Behavior Disorders; Humans; Nitriles; Phenothiazines; Piperidines; Tranquilizing Agents